Autopsy report · NCT00866333

A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma

“Terminated prior to completion of accrual per corporate decision.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 10 months before it stopped.
• 49 participants enrolled.
• Results were posted on the registry 6 years 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Syndax Pharmaceuticals

Sponsor type

Industry

Conditions

Hodgkin's Lymphoma

Interventions

Entinostat

Participants

49

Sites

6

Countries

United States

Trials that died the same way

• Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
  “Terminated due to inadequate rate of accrual.” (77% match in meaning)
• A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease
  “Terminated due to strategic business decision.” (76% match in meaning)
• A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation
  “Terminated due to business decision” (75% match in meaning)
• Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
  “Terminated due to low accrual.” (75% match in meaning)
• Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)
  “Terminated due to poor accrual” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.